# HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)

> **NCT05775965** · PHASE2 · RECRUITING · sponsor: **University of Calgary** · enrollment: 250 (estimated)

## Conditions studied

- Hip Fractures

## Interventions

- **DRUG:** Rivaroxaban 10mg
- **DRUG:** acetylsalicylic acid (ASA) 81mg Oral Tablet

## Key facts

- **NCT ID:** NCT05775965
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2025-03
- **Final completion:** 2026-03-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05775965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05775965, "HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05775965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*